Cargando…

Thermosensitive Exosome–Liposome Hybrid Nanoparticle‐Mediated Chemoimmunotherapy for Improved Treatment of Metastatic Peritoneal Cancer

Metastatic peritoneal carcinoma (mPC) is a deadly disease without effective treatment. To improve treatment of this disease, a recently developed hyperthermic intraperitoneal chemotherapy (HIPEC) has emerged as the standard of care. However, the efficacy of this approach is limited by inefficient dr...

Descripción completa

Detalles Bibliográficos
Autores principales: Lv, Qijun, Cheng, Lili, Lu, Yao, Zhang, Xiaoge, Wang, Yizhen, Deng, Junfeng, Zhou, Jiangbing, Liu, Bo, Liu, Jie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7509655/
https://www.ncbi.nlm.nih.gov/pubmed/32999828
http://dx.doi.org/10.1002/advs.202000515
_version_ 1783585642660233216
author Lv, Qijun
Cheng, Lili
Lu, Yao
Zhang, Xiaoge
Wang, Yizhen
Deng, Junfeng
Zhou, Jiangbing
Liu, Bo
Liu, Jie
author_facet Lv, Qijun
Cheng, Lili
Lu, Yao
Zhang, Xiaoge
Wang, Yizhen
Deng, Junfeng
Zhou, Jiangbing
Liu, Bo
Liu, Jie
author_sort Lv, Qijun
collection PubMed
description Metastatic peritoneal carcinoma (mPC) is a deadly disease without effective treatment. To improve treatment of this disease, a recently developed hyperthermic intraperitoneal chemotherapy (HIPEC) has emerged as the standard of care. However, the efficacy of this approach is limited by inefficient drug penetration and rapidly developed drug resistance. Herein, a nanotechnology approach is reported that is designed to improve drug delivery to mPC and to augment the efficacy of HIPEC through delivery of chemoimmunotherapy. First, the drug delivery efficiency of HIPEC is determined and it is found that chemotherapy agents cannot be efficiently delivered to large tumors nodules. To overcome the delivery hurdle, genetically engineered exosomes‐thermosensitive liposomes hybrid NPs, or gETL NPs, are then synthesized, and it is demonstrated that the NPs after intravenous administration efficiently penetrates into mPC tumors and releases payloads at the hypothermia condition of HIPEC. Last, it is shown that, when granulocyte‐macrophage colony‐stimulating factor (GM‐CSF) and docetaxel are co‐delivered, gETL NPs effectively inhibit tumor development and the efficacy is enhanced when HIPEC is co‐administered. The study provides a strategy to improve drug delivery to mPCs and offers a promising approach to improve treatment of the disease through combination of locoregional delivery of HIPEC and systemic delivery of chemoimmunotherapy via gETL NPs.
format Online
Article
Text
id pubmed-7509655
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-75096552020-09-29 Thermosensitive Exosome–Liposome Hybrid Nanoparticle‐Mediated Chemoimmunotherapy for Improved Treatment of Metastatic Peritoneal Cancer Lv, Qijun Cheng, Lili Lu, Yao Zhang, Xiaoge Wang, Yizhen Deng, Junfeng Zhou, Jiangbing Liu, Bo Liu, Jie Adv Sci (Weinh) Full Papers Metastatic peritoneal carcinoma (mPC) is a deadly disease without effective treatment. To improve treatment of this disease, a recently developed hyperthermic intraperitoneal chemotherapy (HIPEC) has emerged as the standard of care. However, the efficacy of this approach is limited by inefficient drug penetration and rapidly developed drug resistance. Herein, a nanotechnology approach is reported that is designed to improve drug delivery to mPC and to augment the efficacy of HIPEC through delivery of chemoimmunotherapy. First, the drug delivery efficiency of HIPEC is determined and it is found that chemotherapy agents cannot be efficiently delivered to large tumors nodules. To overcome the delivery hurdle, genetically engineered exosomes‐thermosensitive liposomes hybrid NPs, or gETL NPs, are then synthesized, and it is demonstrated that the NPs after intravenous administration efficiently penetrates into mPC tumors and releases payloads at the hypothermia condition of HIPEC. Last, it is shown that, when granulocyte‐macrophage colony‐stimulating factor (GM‐CSF) and docetaxel are co‐delivered, gETL NPs effectively inhibit tumor development and the efficacy is enhanced when HIPEC is co‐administered. The study provides a strategy to improve drug delivery to mPCs and offers a promising approach to improve treatment of the disease through combination of locoregional delivery of HIPEC and systemic delivery of chemoimmunotherapy via gETL NPs. John Wiley and Sons Inc. 2020-07-29 /pmc/articles/PMC7509655/ /pubmed/32999828 http://dx.doi.org/10.1002/advs.202000515 Text en © 2020 The Authors. Published by WILEY‐VCH Verlag GmbH & Co. KGaA, Weinheim This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Full Papers
Lv, Qijun
Cheng, Lili
Lu, Yao
Zhang, Xiaoge
Wang, Yizhen
Deng, Junfeng
Zhou, Jiangbing
Liu, Bo
Liu, Jie
Thermosensitive Exosome–Liposome Hybrid Nanoparticle‐Mediated Chemoimmunotherapy for Improved Treatment of Metastatic Peritoneal Cancer
title Thermosensitive Exosome–Liposome Hybrid Nanoparticle‐Mediated Chemoimmunotherapy for Improved Treatment of Metastatic Peritoneal Cancer
title_full Thermosensitive Exosome–Liposome Hybrid Nanoparticle‐Mediated Chemoimmunotherapy for Improved Treatment of Metastatic Peritoneal Cancer
title_fullStr Thermosensitive Exosome–Liposome Hybrid Nanoparticle‐Mediated Chemoimmunotherapy for Improved Treatment of Metastatic Peritoneal Cancer
title_full_unstemmed Thermosensitive Exosome–Liposome Hybrid Nanoparticle‐Mediated Chemoimmunotherapy for Improved Treatment of Metastatic Peritoneal Cancer
title_short Thermosensitive Exosome–Liposome Hybrid Nanoparticle‐Mediated Chemoimmunotherapy for Improved Treatment of Metastatic Peritoneal Cancer
title_sort thermosensitive exosome–liposome hybrid nanoparticle‐mediated chemoimmunotherapy for improved treatment of metastatic peritoneal cancer
topic Full Papers
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7509655/
https://www.ncbi.nlm.nih.gov/pubmed/32999828
http://dx.doi.org/10.1002/advs.202000515
work_keys_str_mv AT lvqijun thermosensitiveexosomeliposomehybridnanoparticlemediatedchemoimmunotherapyforimprovedtreatmentofmetastaticperitonealcancer
AT chenglili thermosensitiveexosomeliposomehybridnanoparticlemediatedchemoimmunotherapyforimprovedtreatmentofmetastaticperitonealcancer
AT luyao thermosensitiveexosomeliposomehybridnanoparticlemediatedchemoimmunotherapyforimprovedtreatmentofmetastaticperitonealcancer
AT zhangxiaoge thermosensitiveexosomeliposomehybridnanoparticlemediatedchemoimmunotherapyforimprovedtreatmentofmetastaticperitonealcancer
AT wangyizhen thermosensitiveexosomeliposomehybridnanoparticlemediatedchemoimmunotherapyforimprovedtreatmentofmetastaticperitonealcancer
AT dengjunfeng thermosensitiveexosomeliposomehybridnanoparticlemediatedchemoimmunotherapyforimprovedtreatmentofmetastaticperitonealcancer
AT zhoujiangbing thermosensitiveexosomeliposomehybridnanoparticlemediatedchemoimmunotherapyforimprovedtreatmentofmetastaticperitonealcancer
AT liubo thermosensitiveexosomeliposomehybridnanoparticlemediatedchemoimmunotherapyforimprovedtreatmentofmetastaticperitonealcancer
AT liujie thermosensitiveexosomeliposomehybridnanoparticlemediatedchemoimmunotherapyforimprovedtreatmentofmetastaticperitonealcancer